Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17833682 | 1.00 | ANPEP (0.46) | ANPEPLTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5679211 | 1.00 | ANPEP (0.46) | ANPEPLTA4HSLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL5682971 | 0.98 | ANPEP (0.44) | ANPEPLTA4HSLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL5681286 | 0.98 | ANPEP (0.44) | ANPEPLTA4HSLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL5683191 | 0.98 | ANPEP (0.44) | ANPEPLTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL14195280 | 0.85 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1CYP2D6MEN1 | |
| SCHEMBL13696735 | 0.85 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1CYP2D6MEN1 | |
| SCHEMBL7965733 | 0.85 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1CYP2D6MEN1 | |
| SCHEMBL29250597 | 0.85 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1CYP2D6MEN1 | |
| SCHEMBL20194387 | 0.85 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1CYP2D6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1144348-B1 | LTA 4 HYDROLASE INHIBITORS | BIOPROJET SOC CIV (FR) | 2006-02-08 | — | — | EP | claimed |
| EP-1144348-A3 | LTA 4? HYDROLASE INHIBITORS | BIOPROJET (FR) | 2002-09-11 | — | — | EP | claimed |
| EP-1144348-A2 | LTA 4? HYDROLASE INHIBITORS | BIOPROJET (FR) | 2001-10-17 | — | — | EP | claimed |
| WO-2000017133-A2 | LTA4 HYDROLASE INHIBITORS | BIOPROJET (FR) | 2000-03-30 | — | — | WO | claimed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| EP-1144348-B1 | LTA 4 HYDROLASE INHIBITORS | BIOPROJET SOC CIV (FR) | 2006-02-08 | — | — | EP | disclosed |
| EP-1144348-A3 | LTA 4? HYDROLASE INHIBITORS | BIOPROJET (FR) | 2002-09-11 | — | — | EP | disclosed |
| EP-1144348-A2 | LTA 4? HYDROLASE INHIBITORS | BIOPROJET (FR) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000017133-A2 | LTA4 HYDROLASE INHIBITORS | BIOPROJET (FR) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | ANPEP 2723/4885LTA4H 6/4885SLC1A3 1944/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | ANPEP 2723/4885LTA4H 6/4885SLC1A3 1944/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | ANPEP 4143/4885LTA4H 2/4885SLC1A3 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.